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Abstract
Background: An effective vaccine against Bordetella pertussis was introduced into the Expanded Programme on
Immunisation (EPI) by WHO in 1974, leading to a substantial global reduction in pertussis morbidity and mortality.
In low- and middle-income countries (LMICs), however, the epidemiology of pertussis remains largely unknown.
This impacts negatively on pertussis control strategies in these countries. This study aimed to systematically and
comprehensively review published literature on the burden of laboratory-confirmed pertussis in LMICs over the 45
years of EPI.
Methods: Electronic databases were searched for relevant literature (1974 to December 2018) using common and
MeSH terms for pertussis. Studies using PCR, culture or paired serology to confirm Bordetella pertussis and
parapertussis in symptomatic individuals were included if they had clearly defined numerators and denominators to
determine prevalence and mortality rates.
Results: Eighty-two studies (49,167 participants) made the inclusion criteria. All six WHO regions were represented
with most of the studies published after 2010 and involving mainly upper middle-income countries (n = 63; 77%).
PCR was the main diagnostic test after the year 2000.
The overall median point prevalence of PCR-confirmed Bordetella pertussis was 11% (interquartile range (IQR), 5–
27%), while culture-confirmed was 3% (IQR 1–9%) and paired serology a median of 17% (IQR 3–23%) over the
period. On average, culture underestimated prevalence by 85% (RR = 0.15, 95% CI, 0.10–0.22) compared to PCR in
the same studies.
Risk of pertussis increased with HIV exposure [RR, 1.4 (95% CI, 1.0–2.0)] and infection [RR, 2.4 (95% CI, 1.1–5.1)]. HIV
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infection and exposure were also related to higher pertussis incidences, higher rates of hospitalisation and
pertussis-related deaths.
Pertussis mortality and case fatality rates were 0.8% (95% CI, 0.4–1.4%) and 6.5% (95% CI, 4.0–9.5%), respectively.
Most deaths occurred in infants less than 6 months of age.
Conclusions: Despite the widespread use of pertussis vaccines, the prevalence of pertussis remains high in LMIC
over the last three decades. There is a need to increase access to PCR-based diagnostic confirmation in order to
improve surveillance. Disease control measures in LMICs must take into account the persistent significant infant
mortality and increased disease burden associated with HIV infection and exposure.
Keywords: Pertussis, Burden, Prevalence, Incidence, Mortality, Case fatality, HIV, Low- and middle-income countries
(LMIC)
Background
Pertussis is a highly infectious respiratory illness caused
by Bordetella pertussis or Bordetella parapertussis. Using
a model developed in 2003, the World Health
Organization (WHO) estimated that in 2008 there were
20 to 40 million annual cases of pertussis. They further
estimated that 90% of the cases and their 300,000 associ-
ated deaths occurred in low- and middle-income coun-
tries (LMICs) [1, 2]. An updated model by WHO
estimated that 24.1 million cases of pertussis occurred in
2014 with 160,700 associated deaths in children under
5 years of age; a majority of these (58%) were estimated
to have occurred in the African region and largely in-
volved infants (53%) [3].
While there are good surveillance data to support the
re-emergence of pertussis in high-income countries
(HICs), the disease trends are unknown in LMICs due to
the paucity of epidemiological data in these settings [4,
5]. A non-systematic review of available data for the Af-
rican continent was published recently by the Global
Pertussis Initiative (GPI) [6].
The high HIV prevalence estimates in LMICs coupled
with suboptimal vaccine uptake are modifiable risk fac-
tors that can fuel high pertussis burdens [7, 8]. The per-
tussis resurgence reported lately in HICs has resulted in
the review of disease control strategies in these countries
[4, 9]. A review of existing pertussis control programmes
in LMICs is yet to be undertaken.
The availability of an effective vaccine against Borde-
tella pertussis since the 1940s has led to a substantial
global reduction in the morbidity and mortality caused
by pertussis [10]. In 1974, WHO included the whole cell
vaccine (wP) in the Expanded Programme on Immunisa-
tion (EPI) adopted in several countries. Although wP is
still widely used in many LMICs, many HICs have re-
placed wP with various formulations of the acellular vac-
cine (aP) [11]. Epidemiological data from HICs show
that despite high vaccine coverage with aP, the pertussis
burden has increased in non-immunised and partially
immunised infants, as well as in previously immunised
adolescents and adults [4, 9, 12–14]. The reported per-
tussis resurgence has been linked to several factors such
as reduced efficacy of aP vaccines and genetic evolution
of the pertussis bacteria as well as improved diagnosis
and reporting of the disease [5].
A sound understanding of trends in the burden of per-
tussis is required to assess the impact of current pertus-
sis control strategies as well as to decide on future
policy. We conducted a comprehensive systematic re-
view to address the knowledge gap in the longitudinal
epidemiology of pertussis in LMICs for the 45 years
starting in 1974 to 2018, inclusive. Primarily, our sys-
tematic review aimed to review available published lit-
erature on the prevalence and/or incidence of
laboratory-confirmed pertussis in LMICs since the in-
ception of the EPI and to determine the trend in the
burden of pertussis in LMICs from 1974. For secondary
objectives, we sought to determine the mortality and
case fatality rates ascribed to pertussis in LMICs, as well
as to investigate the impact of vaccine choice, and HIV
infection and in utero exposure on the burden of pertus-
sis in LMICs over the review period.
Methods
Search strategy and criteria for selecting studies
The protocol for the systematic review was registered
with PROSPERO International Prospective Register of
systematic reviews (http://www.crd.york.ac.uk/PROS-
PERO), with registration CRD42015015159. The
methods employed in conducting this review have been
previously published [15]. The following electronic data-
bases were searched for qualifying literature: MEDLINE,
Scopus, Africa-Wide, PDQ-Evidence, WHOLIS, CINA
HL, CENTRAL and Web of Science. Search terms used
included “pertussis,” “Bordetella pertussis”, “Bordetella
parapertussis” and “whooping cough” combined with
“burden”, “epidemiology”, “incidence”, “prevalence” and
“case”. These were used together with the specific names
of all LMICs as classified by the World Bank [16, 17].
The search strategy as used in MEDLINE via PubMed is
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shown in Additional file 1. The reported search was car-
ried out in April 2019. The World Bank groupings re-
flect the country status at this period.
The search was limited to studies published from
1974, the year that the EPI was introduced, until Decem-
ber 2018. Titles and abstracts of the search outputs and
references were screened, and the full texts of potentially
relevant articles were independently assessed by two re-
viewers (RM and BK) using a standardised score sheet.
Disagreements on final inclusions were resolved by con-
sensus following discussions involving a third reviewer
(GH). Authors and publishers were contacted for full
texts not available online or via our collaborative
networks.
Studies were included if the study populations were
from LMICs. While the diagnosis of pertussis is largely
made on the basis of clinical parameters, it is well-
known that clinical presentation may be modified by
age, previous immunisation or infection, antibiotic ex-
posure and concurrent infection with other pathogens
[10]. This makes the presentation of pertussis frequently
atypical, thus requiring laboratory confirmation of cases
by serology, culture or polymerase chain reaction (PCR).
Therefore, laboratory confirmation by either PCR, cul-
ture or paired serological assays was also an inclusion
criterion.
Studies that failed to provide a numerator (number of
participants testing positive) or denominator (number of
participants tested for pertussis), as well as those that
failed to specify the laboratory diagnostic method uti-
lised, were excluded. Studies on sero-epidemiological
and laboratory diagnostic methods in the absence of
clinical disease were also excluded.
The systematic review included published randomised
controlled trials, cross-sectional, cohort and surveillance
studies. Case series and review articles were excluded as
they failed to provide the required denominator.
Data extraction
The denominator and numerator were extracted from
each study to determine the prevalence for each diag-
nostic method. We defined prevalence as proportions
with confirmed laboratory diagnosis from all participants
suspected and tested for pertussis. Bordetella pertussis
prevalence data were stratified by WHO region, diagnos-
tic method (culture, paired serology or PCR), clinical set-
ting (hospital or population based) and age category of
the study participants. Prevalence was further stratified
by HIV status, that is HIV infected (HIV+), HIV-
exposed uninfected (HEU) and HIV-unexposed unin-
fected (HUU). Incidence data were extracted as reported
by the authors.
The epidemiology of Bordetella parapertussis was sep-
arately assessed. Data on the type of pertussis vaccine
(wP or aP) used, clinical diagnostic criteria (e.g. WHO,
Centers for Disease Control and Prevention (CDC), etc.)
and the study design were captured.
Foreign language articles were reviewed, and data ex-
tracted with the assistance of online translation pro-
grammes and native speakers [18, 19].
Data analysis and reporting
Percentage point estimates together with their 95% con-
fidence intervals (CIs) were calculated to represent the
prevalence of laboratory-confirmed pertussis for all out-
comes. The Mantel-Haenszel method was used to pool
together prevalence data from individual studies using
random-effects meta-analysis. Heterogeneity was evalu-
ated both visually by assessing forest plots and formally
using the χ2-based Q and I2 statistics [20]. Where a
meta-analysis was not feasible, either because data were
too heterogeneous or insufficient to allow for meaningful
pooling, narrative reporting was used.
Narratively reported frequencies were summarised
using medians and interquartile ranges (IQR) of preva-
lence point estimates and graphically represented using
forest-like plots that omitted pooled data. Instead, dotted
lines were used to indicate where group averages would
lie without emphasising their meaning. The Kruskal-
Wallis test was used to compare point prevalence be-
tween groups.
Mortality was defined as the proportion of deaths at-
tributable to pertussis in the study sample while case fa-
tality was defined as mortality attributable to the disease
among confirmed cases of pertussis.
The incidence of pertussis could not be independently
estimated as the requisite data was not available. Inci-
dence was narratively reported per 100,000 as reported
by the authors themselves.
All statistical analyses were done on STATA software
version 14 (STATA Corporation, College Station, TX).
The command metaprop_one was used to generate
pooled prevalence forest plots after Freeman-Tukey
transformation and metan, for comparative effect forest
plots showing relative risks (RR) and their 95% CI,
respectively.
The study utilised the guidelines for reporting system-
atic reviews as set down by the revised 2009 PRISMA
Statement [21].
Quality of included studies
An adaptation of the tool developed by Wasserman et al.
was used to assess the risk of bias as well as the quality
of the included studies [22]. The quality assessment cri-
teria examined specific variables to make judgement on
the studies, taking into account methodological aspects
discussed by Hoy et al. pertaining to internal and exter-
nal validity of prevalence studies [23].
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Results
Characteristics of the included studies
The search strategy returned 3186 studies which re-
duced to 2633 after excluding duplicates. Following
screening of abstracts and titles, 275 articles were
deemed potentially relevant and subjected to full-text
evaluation. Eighty-two studies (n = 49,167) met the final
criteria for inclusion into the systematic review (Fig. 1).
Studies were excluded if they did not report clinical
cases such as in laboratory studies, animal studies, eco-
nomic evaluation and modelling studies. Other reasons
for exclusions are shown in Fig. 1. The included studies
involved symptomatic individuals meeting WHO and
CDC (n = 52 and n = 8 respectively) clinical criteria. The
remaining studies (n = 22) used clinical definitions
derived from modifications of the criteria set by WHO
or CDC. Two studies were multinational (two and seven
countries in each) so that in the end the final 82 studies
included, represented 88 unique populations [24, 25].
Table 1 shows the characteristics of the included stud-
ies by WHO region. A large proportion of the studies
(n = 63; 77%) was published between 2010 and 2018.
Sixty-eight studies (83%) involved hospital-based partici-
pants. Forty-seven studies (57%) used one laboratory
diagnostic confirmatory test while 32 (39%) and three
(4%) studies used two and three methods for pertussis
diagnosis, respectively.
Study designs included three clinical trials, four co-
horts, 62 cross-sectional and 13 surveillance studies.
There were 71 studies published in English, four in
Fig. 1 Studies included in the systematic review
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Table 1 Characteristics of studies included in the systematic review
Region and study Design Setting Diagnosis Country Vaccine Period Sample (cases)
Africa
Voorhoeve# (1978) [26] Surveillance Population C, S Kenya wP 1974–19077 1078 (138)
Ramkissoon (1991) [27] Clinical trial Population S South Africa wP 1988 112 (3)
Strebel (1991) [28] Surveillance Hospital C, S South Africa wP 1989 34 (3)
Simondon (1997) [29] Clinical trial Population C, P, S Senegal wP and aP 1990–1995 3619 (193)
Anukam# (2004) [30] Cross-sectional Hospital C Nigeria wP 1997–2000 296 (22)
Lassmann (2008) [31] Cross-sectional Hospital P Gabon wP 2003–2004 99 (6)
Jusot# (2014) [32] Cross-sectional Hospital C, P Niger wP 2010–2011 305 (34)
Kayina (2016) [33] Cross-sectional Hospital P Uganda wP 2013 449 (67)
Barger-Kamate (2016) [24] Cross-sectional Hospital P Multinational wP and aP 2011–2014 3451 (52)
Gill (2016) [34] Cohort Population P Zambia wP 2015 775 (10)
Hallbauer# (2016) [35] Cross-sectional Hospital P South Africa aP 2008–2015 1259 (183)
Muloiwa# (2016) [36] Cross-sectional Hospital C, P South Africa aP 2011–2012 460 (41)
Nunes (2016) [37] Clinical trial Population P South Africa aP 2011–2012 1644 (79)
Soofie (2016) [38] Cross-sectional Hospital P South Africa aP 2015 1839 (42)
Zar (2016) [39] Cohort Population P South Africa aP 2012–2014 284 (16)
du Plessis# (2018) [40] Surveillance Hospital C, P South Africa aP 2013–2015 990 (76)
Eastern Mediterranean
Al-Bargish# (1999) [41] Cross-sectional Hospital C Iran wP 1996 133 (67)
Kakar (2009) [42] Surveillance Hospital C Afghanistan wP 2006–2007 203 (7)
Ghanaie# (2010) [43] Cross-sectional Population C, P Iran wP 2007–2008 328 (27)
Bokhari# (2011) [44] Cross-sectional Hospital C, P Pakistan wP 2005–2009 802 (64)
Hajia (2012) [45] Cross-sectional Hospital P Iran wP 2008–2011 138 (12)
Mughal (2012) [46] Cross-sectional Hospital C Pakistan wP 2004–2006 700 (22)
Zouari# (2012) [47] Cross-sectional Hospital C, P Tunisia wP 2007–2011 599 (120)
Bahari (2013) [48] Cross-sectional Hospital C Iran wP 2008–2012 156 (7)
Nikbin (2013) [49] Cross-sectional Hospital C, P Iran wP 2009–2010 779 (100)
Saffar (2014) [50] Cross-sectional Hospital P Iran wP 2008–2012 518 (43)
Sedaghat# (2014) [51] Cross-sectional Hospital C, P Iran wP 2004–2008 347 (30)
Benamrouche (2016) [52] Surveillance Hospital C, P Algeria wP 2012–2013 246 (123)
Ghorbani (2016) [53] Surveillance Hospital P Iran wP 2011–2013 3629 (239)
Omer (2016) [54] Surveillance Hospital P Pakistan wP 2015–2016 2021 (8)
Katfy# (2017) [55] Cross-sectional Hospital C, P Morocco wP 2013–2015 156 (88)
Ben Fraji# (2018) [56] Cross-sectional Hospital C, P Tunisia wP 2007–2017 1844 (306)
Dumaidi (2018) [57] Cross-sectional Hospital P West Bank wP 2004–2008 267 (130)
Mohammadzadeh (2018) [58] Cross-sectional Hospital C, P Iran wP 2015–2016 184 (43)
Europe
Lukić-Grlić# (1999) [59] Cross-sectional Hospital C, S Croatia wP 1988–1994 201 (2)
Daǧla (2004) [60] Cross-sectional Hospital C Turkey wP 2001–2003 66 (2)
Aksakal (2007) [61] Cross-sectional Population S Turkey wP 2004 307 (51)
Yıldırım (2008) [62] Cross-sectional Hospital P, S Turkey wP 2005–2006 148 (16)
Medkova (2010) [63] Cross-sectional Unclear C, P Russian Fed. wP Unknown 172 (81)
Gürsel (2012) [64] Cross-sectional Hospital C, P, S Turkey aP 2009–2010 51 (6)
Karlı (2013) [65] Cross-sectional Hospital C, P Turkey aP 2008–2012 40 (6)
Uslu (2013) [66] Cross-sectional Hospital P Turkey aP 2012 173 (48)
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Table 1 Characteristics of studies included in the systematic review (Continued)
Region and study Design Setting Diagnosis Country Vaccine Period Sample (cases)
Dinu (2014) [67] Cross-sectional Hospital C, P, S Romania aP 2012–2013 51 (14)
Karagül (2014) [68] Cross-sectional Hospital C, P Turkey aP 2010–2011 214 (26)
Öksüz# (2014) [69] Cross-sectional Hospital C, P Turkey aP 2010–2013 410 (106)
Aslan (2016) [70] Cross-sectional Hospital P Turkey aP 2013–2014 101 (20)
Goktas (2016) [71] Cross-sectional Hospital P Turkey aP 2014–2015 845 (15)
Gökçe (2018) [72] Cross-sectional Hospital P Turkey aP 2013–2016 172 (44)
South-East Asia
Singh (1987) [73] Cross-sectional Hospital C India wP c.1986 560 (20)
Dahiya (2009) [74] Cross-sectional Hospital C, P India wP 2007–2007 21 (2)
Barger-Kamate (2016) [24] Cross-sectional Hospital P Multinational wP 2011–2014 749 (1)
Das (2016) [75] Cross-sectional Hospital P India wP 2013–2014 180 (7)
Siriyakorn (2016) [76] Cross-sectional Hospital P Thailand wP 2010–2011 76 (14)
Hughes# (2017) [77] Cohort Population P Nepal wP 2011–2014 2026 (17)
Chinthate (2018) [78] Cross-sectional Hospital P Thailand wP 2016–2017 70 (7)
The Americas
Cooper (1983) [79] Surveillance Hospital C, S St Lucia wP 1981 10 (2)
Baptista (2006) [80] Cross-sectional Hospital C Brazil wP 2003 287 (51)
Kowalzik (2007) [25] Cross-sectional Hospital P Multinational wP and aP 2001–2004 181 (19)
Sandoval (2008) [81] Cross-sectional Population P Mexico wP 2002–2003 61 (20)
Nieto Guevara (2010) [82] Surveillance Hospital C, P Panama wP and aP 2001–2008 759 (178)
Astudillo (2011) [83] Cross-sectional Hospital C, P Colombia wP 2006–2007 133 (45)
Leite (2012) [84] Surveillance Hospital C Brazil wP 2006–2008 652 (132)
Ferronato (2013) [85] Cohort Hospital C, P Brazil wP 2009–2012 57 (25)
Ochoa-Perez (2014) [86] Surveillance Hospital C, P Mexico aP 2011–2012 147 (59)
Vaz-de-Lima (2014) [87] Surveillance Hospital P Brazil wP 2009–2012 503 (66)
Castillo (2015) [88] Cross-sectional Hospital P Peru wP 2010–2012 392 (155)
Pavic-Espinoza (2015) [89] Cross-sectional Hospital P Peru wP 2009–2010 596 (114)
Pimentel (2015) [90] Cross-sectional Hospital C, P Brazil wP 2010–2011 192 (10)
del Valle-Mendoza (2015) [91] Cross-sectional Hospital P Peru wP 2010–2013 133 (51)
Bailon# (2016) [92] Cross-sectional Hospital C, P Peru wP 2012 840 (191)
Aquino-Andrade# (2017) [93] Cross-sectional Hospital P Mexico aP 2011–2014 286 (192)
Phadke (2018)# [94] Cross-sectional Hospital P Guatemala wP 2009–2012 301 (11)
del Valle-Mendoza (2018) [95] Cross-sectional Hospital P Peru wP 2016–2017 88 (18)
Western Pacific
Ong (1978) [96] Cross-sectional Hospital C Malaysia wP 1974 65 (1)
Lin (2010) [97] Cross-sectional Hospital C, P China wP 2008–2009 1001 (99)
Mi (2013) [98] Cross-sectional Hospital P China wP 2011–2012 176 (51)
Ting (2013) [99] Cross-sectional Hospital C, P Malaysia wP 2011 707 (275)
Huang (2014) [100] Surveillance Population P China wP and aP 2010–2012 1022 (113)
Liu (2014) [101] Cross-sectional Hospital C, P China wP 2013 148 (101)
Wang (2014) [102] Cross-sectional Hospital C, P China wP and aP 2012–2013 313 (122)
Hu (2015) [103] Cross-sectional Hospital P China aP 2013–2014 2536 (247)
Moriuchi (2017) [104] Cross-sectional Unclear P Cambodia wP 2008–2016 651 (82)
Sadiasa (2017) [105] Cross-sectional Hospital P Philippines wP 2012–2015 1152 (34)
C culture, P polymerase chain reaction, S paired serology, wP whole cell vaccine, aP acellular vaccine
#Includes Bordetella parapertussis. NB. Cooper, Strebel and Al-Bargish conducted in outbreak settings
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Mandarin, three each in Spanish and Turkish and one in
Persian. Three studies by Cooper and Fitch, Strebel et al.
and Al-Bargish et al. were conducted in outbreak set-
tings [28, 41, 79].
In total, the studies originated from 37 countries,
representing all six WHO regions (Additional file 2).
Nineteen (51%) of the countries represented were upper
middle-income, while 11 (30%) and seven (19%) were
lower middle- and low-income countries, respectively.
Five countries contributed 28 (49%) of the studies
(Turkey = 11, Iran = 9, South Africa = 8, China = 6 and
Brazil = 6). Sixty-four (78%) studies had epidemiological
data for Bordetella pertussis only while 18 (22%) studies
investigated for both Bordetella pertussis and Bordetella
parapertussis. The most frequently used vaccine over
the period the included studies were conducted was wP
in 72/88 (82%) settings either on its own (n = 66) or in
combination with aP (n = 6). In 16 (18%) settings, aP
was the only vaccine in use.
Data from a study by Zouari et al. was considered only
for the purpose of estimating mortality but not for esti-
mation of disease burden as its data overlapped with that
of Ben Fraj et al. who reported cases over a longer
period but did not report on mortality [47, 56].
Prevalence of pertussis
The median prevalence of PCR-confirmed disease due to
Bordetella pertussis was 11% (IQR, 5–27%; n = 43,696,
64 studies) (Fig. 2 and Additional file 3). PCR prevalence
differed across WHO regions ranging from a median of
4% (IQR 4–10%) in South-East Asia to a median of 22%
(IQR 12–40%) in the Region of the Americas, P = 0.001.
In one multinational study, conducted in countries in the
Africa and South-East Asia regions, Barger-Kamate et al.
found an increased risk for pertussis in African countries
with an adjusted odds ratio of 8.8 (P = 0.03) [24].
The median prevalence of culture-confirmed Borde-
tella pertussis was 3% (IQR 1–9%) (n = 18,868, 44 stud-
ies). The point prevalence was similar across WHO
regions, P = 0.1380 (Fig. 3 and Additional file 2).
Confirmation of Bordetella pertussis using paired ser-
ology showed a median of 17% (IQR 3–23%; n = 4912, 9
studies). Only three WHO regions were represented,
and the median prevalence was 3% (IQR 3–13%) in the
African region and 17% (95% CI, 13–26%) in the Euro-
pean region, while the one country, St Lucia, represent-
ing the Region of the Americas had a prevalence of 44%
(95% CI, 14–79%), P = 0.1309 (Additional file 3 and
Additional file 4).
The prevalence of confirmed Bordetella parapertussis
infection using any of the three confirmatory methods
was 1% (IQR, 0–2%; n = 12,062, 18 studies). The Eastern
Mediterranean region was noted to have the highest
prevalence with a median 2% (IQR 0–7%) with one study
from the same region having a prevalence of 19% (95%
CI 13–26%) [41] (Additional file 5).
The prevalence of Bordetella pertussis differed in the
same population depending on the method of laboratory
confirmation used. On average, culture underestimated
prevalence by 85% (RR = 0.15, 95% CI, 0.10–0.22) com-
pared to PCR in the 29 (n = 14,315) studies that used
both methods (Additional file 6).
Pertussis prevalence declined in the 1990s from the
levels seen in the 1970s and 1980s. A slight increase was
noted since the period after 2000 (Fig. 4a). Huang et al.
reported a 26-fold increase in confirmed adult pertussis
between 2010 and 2014 in China [100]. There was suffi-
cient information in 48 studies to estimate age preva-
lence by age group. The lowest prevalence was noted in
individuals older than 19 years with a median prevalence
of 6% (IQR 5–14%). After the high prevalence noted
below 5 years of age, the risk declined in late childhood
(6 to 10 years) but increased again in adolescents who
showed the highest prevalence of all groups with a me-
dian prevalence of 20% (IQR 14–32%) (Fig. 4b).
Pertussis prevalence was also stratified by the study set-
ting (hospital versus population based) as well as by the
type of vaccine used in settings where the included studies
were conducted. The prevalence of pertussis in hospital-
based studies had a median of 10% (IQR 4–25%) com-
pared to population-based studies which reported a me-
dian prevalence of 6% (IQR 3–13%). There was an overlap
in the distribution of prevalence of confirmed pertussis in
populations using aP only [median 10% (IQR 6–28%)]
compared to populations using some wP [median 10%
(IQR 3–20%)]. The overlap remained even when preva-
lence was stratified by the diagnostic method. In the only
included clinical trial comparing the two vaccine types,
Simondon et al. found aP vaccine efficacy against all con-
firmed pertussis to be 85% (95% CI, 66–93%) and that of
wP to be 96% (95% CI, 86–99%) [29].
Incidence of pertussis
Population-level incidence rates of pertussis and hospital-
isation were reported by some of the authors, but these
could not be independently verified as the requisite popu-
lation data were not available (Table 2). In addition, a ma-
jority of the authors reported point estimate incidences
with no confidence intervals. Where data was available for
different age groups (Voorhoeve et al., Nieto Guevara
et al., Saffar et al. and Ochoa-Perez et al.), the incidence
was always highest in infancy [26, 50, 82, 86]. The highest
incidence of 15,900/100000 was reported in Kenyan in-
fants between 1974 and 1977 [26]. In addition to Borde-
tella pertussis incidence, Ghanaie et al. reported a separate
incidence of 2 per 100,000 for Bordetella parapertussis
[43]. Contacts were reported to have an incidence of 0.69/
100000 in Benamrouche et al.’s study [52].
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Fig. 2 Prevalence of polymerase chain reaction-confirmed Bordetella pertussis. Dotted lines show subgroup and whole group average estimates
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Fig. 3 Prevalence of culture-confirmed Bordetella pertussis. Dotted lines show subgroup and whole group average estimates
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Time-denominated rates were recorded for three stud-
ies. Gill et al. reported a rate of 2.4 (95% CI, 1.2–4.2)
cases per 1000 infant-months with the highest rate of
3.5 cases/1000 infant-months noted between birth and
6 weeks, while Hughes et al. reported a rate of 13.3 (95%
CI, 7.7–21.3) cases per 1000 infant-years [34, 77]. Nunes
et al.’s data gave an overall rate of 4.9 per 1000 person-
months, which differed between infants (5.7/1000) and
mothers (4.3/1000) as well as by HIV status as reported
below [37].
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Fig. 4 Distribution of point prevalence of polymerase chain reaction- and culture-confirmed pertussis by period (a) and age group (b)
Table 2 Population and hospitalisation incidence rates of Bordetella pertussis
Study (year) Incidence Age ranges Country
Voorhoeve (1978) [26] 3800/100000 All ages Kenya
Strebel# (1991) [28] 187/100000 6 months to 5 years South Africa
Simondon (1997) [29] 119/100000 2 months to 15 years Senegal
Sandoval (2008) [81] 500/100000 12 to 15 years Mexico
Ghanaie (2010) [43] 318/100000 6 to 14 years Iran
Nieto Guevara# (2010) [82] 144/100000 All ages Panama
Uslu (2013) [66] 0.9/100000 < 5 years Turkey
Huang (2014) [100] 23.52/100000 All ages China
Jusot (2014) [32] 820/100000 < 5 years Niger
Ochoa-Perez (2014) [86] 2.3/100000 0 to > 18 years Mexico
Saffar (2014) [50] 4.92/100000 0 month to 25 years Iran
Benamrouche (2016) [52] 1.04/100000 All ages Algeria
Gill (2016) [34] 520/100000 < 1 year Zambia
Muloiwa# (2016) [36] 526/100000 < 13 years South Africa
Omer (2016) [54] 247/100000 < 1 year Pakistan
Soofie (2016) [38] 220/100000 < 1 year South Africa
Giayetto (2017) [106] 4.53/100000 All ages Argentina
Ben Fraj (2018) [56] 134/100000 < 5 years Tunisia
#Incidence represents hospitalisation rates for pertussis
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Risk of pertussis in HIV exposed and infected
Ten studies, all from the Africa region, investigated the
impact of HIV status on the risk of pertussis. The inci-
dence rate of pertussis was 7.4/1000 infant-months in
HEU infants and 5.5/1000 in HUU infants in the study
by Nunes et al., while the rates in HIV+ and HIV unin-
fected mothers were 6.8 and 3.9/1000, respectively [37].
Gill et al. reported RR 1.8 (95% CI, 95% CI 0.5–6.9) in
HEU infants compared to HUU. The incidence of Borde-
tella pertussis-associated hospitalisation was 2.9 (95% CI,
1.8–4.5) and 1.9 (95% CI, 1.3–2.6) per 1000 in HIV-
exposed and HIV-unexposed infants, respectively, in a
study by Soofie et al. The reported 4.8% case fatality rate
in Soofie et al. was only due to deaths in HIV-exposed
infants [38]. In the study by Hallbauer et al., there was
insufficient data to estimate stratum-specific rates, but
HIV+ cases, who made 14% of the study sample,
accounted for 22 (19%) of the 113 pertussis cases with
known HIV status [35]. A gradual increase in risk of per-
tussis was reported in a study by Muloiwa et al. in which
the risk of pertussis was 5.4% in HUU, 10.9% in HEU
and 15.8% in HIV+ [36].
There was sufficient data to do a meta-analysis com-
paring risk of pertussis in HUU with HEU and HIV+ in
six and five studies, respectively. Compared to HUU,
HIV+ and HEU individuals had a RR 1.51 (95% CI,
1.02–2.23) and RR 1.4 (95% CI, 1.01–1.92) for confirmed
pertussis, respectively (Fig. 5). The highest risk of
pertussis was reported by Anukam et al., in a cohort of
wP-vaccinated HIV-infected adolescents who were not on
antiretroviral therapy with RR 22.8 (95% CI, 6.9–75.1) [30].
This study was not included in the HIV meta-analysis as it
was an obvious outlier composed of individuals not on
treatment which seemed to show excessive risk for pertus-
sis. All other studies involved HIV+ individuals on anti-
retroviral therapy.
Mortality rate and case fatality rate of pertussis
A total of 97 pertussis-related deaths out of 1490 confirmed
cases were reported in 16 studies (n = 14,390) representing
13 countries. All deaths were associated with Bordetella
pertussis with none attributed to Bordetella parapertussis.
From the 16 studies, the overall mortality rate was 0.8%
(95% CI, 0.4–1.5%) with a pertussis case fatality rate of 5.5%
(95% CI, 3.3–6.1%) (Fig. 6). When only infants were consid-
ered (13 studies), the case fatality rate was 7.2% (95% CI,
3.6–11.8%) in the studies reporting deaths.
All children who died were younger than 5 years and
the majority were younger than 6 months of age. Almost
all deaths occurred under 1 year of age with only one
study (Voorhoeve et al.) reporting pertussis deaths after
the second year of life (n = 5) [26].
Quality of the included studies
Using the modified tool published with the protocol for
this systematic review, we found all the included studies
Fig. 5 Meta-analysis of the relative risk of pertussis comparing HIV-unexposed uninfected (HUU) to HIV-exposed uninfected (HEU) (a) and HIV
infected (b)
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to be of high quality [15]. This is because components of
the quality index score, such as laboratory confirmation
and availability of raw denominator and numerator data
formed part of the inclusion criteria, which automatically
excluded poor-quality studies. Similarly, studies had
moderate to low risk of attrition and selection bias.
Discussion
This study comprehensively reports on the burden of
confirmed pertussis over a 45-year period (1974–2018)
in LMICs. This period starts in 1974 with the inception
of EPI. The prevalence of confirmed pertussis disease
differed in the same study depending on the method of
laboratory confirmation with PCR showing the greatest
diagnostic sensitivity as expected [5]. Most cases were
due to Bordetella pertussis. Bordetella parapertussis was
less common and did not have any reported fatalities
associated with it. The study indicates that pertussis
deaths are significantly high in LMICs with a dispropor-
tionate case fatality rate in young infants. Secondly, the
meta-analysis shows that HIV has a significant impact in
the burden of pertussis in settings where the burden of
HIV is high.
Not surprisingly, the findings from our study agree with
those from some HICs: the highest incidence of pertussis
was in infants and the greatest pertussis-specific mortality
in children younger than 6months [107–109]. Moreover,
we also noted the increase in the prevalence of pertussis
in adolescents similarly described in highly vaccinated co-
horts from HICs [110–112]. The noted decline in adult-
hood may indicate protection following the natural
boosting in adolescence. Worryingly, the pooled case fatal-
ity rate of nearly 6% exceeds the less than 4% estimated by
WHO for developing countries [2]. As noted, this is even
higher when only infants are considered.
The prevalence data presented in this systematic re-
view suggests that LMICs may also be experiencing a re-
surgence of pertussis as noted in HICs. Both the GPI
and WHO advocate for the strengthening of surveillance
systems as a key component in the control of pertussis
[110, 113]. Currently, surveillance of pertussis in LMICs
is suboptimal. As a result, there are many gaps in accur-
ate pertussis epidemiological data which we observed in
this study. The review indicates that the choice of la-
boratory case confirmation influences the quantification
of pertussis disease burden within the same setting. This
is an important finding that suggests that the use of PCR
to confirm pertussis should be prioritised in LMICs. The
higher sensitivity of PCR is more likely to capture the
true burden of pertussis and give a better understanding
of the global epidemiological pattern of the disease
across different settings than any other method. In con-
trast, culture, recognised as the diagnostic gold standard,
missed on average 85% of cases identified by PCR in the
studies that used both methods in this systematic review.
Higher culture prevalence estimates than in other
Fig. 6 Mortality and case fatality rate of confirmed pertussis
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studies in a similar WHO group were noted when the
studies were conducted before a vaccination programme
was fully established (Voorhoeve et al.), during an out-
break (Cooper and Fitch [79]; Strebel et al.; and Al-
Bargish) and when the study included secondary attack
data of close contacts (Astudillo et al.) [26, 28, 41, 83].
A number of authors reported incidences although
population denominators could not be independently veri-
fied as these went largely unreported. The rates were quite
high compared to HICs and showed no pattern of decline
over the period in which the incidences were reported.
An unexpected finding was the significant overlap in
the prevalence of pertussis noted with different vaccines
in use. Most LMICs use wP vaccines in contrast with
the predominant use of aP vaccines in HICs. In general,
wP vaccines are regarded as offering better protection
against pertussis [114]. Despite the predominant use of
wP in the reviewed studies, we noted a steady increase
in confirmed pertussis in studies reporting after 2000.
This suggests that the observed resurgence of pertussis
noted in HIC may only be partly explained by the
change of vaccine from wP to aP in these countries. An-
other possible explanation for the increase may be the
increase in the use of PCR for case confirmation—all the
included studies conducted after 2010 used PCR as the
primary method of confirming cases. The increase in the
observed prevalence coincides with the use of these mo-
lecular techniques.
Although data are limited by the number of countries
reporting HIV status, there is strong evidence from the
meta-analysis showing that the risk of pertussis is in-
creased in HIV+ and HEU individuals. The risk of per-
tussis was increased by 50% and 40% respectively in the
two groups compared to HUU. With the exception of
the study by du Plessis et al., all studies showed an in-
creased risk of pertussis incidence or prevalence associ-
ated with HIV infection or exposure [40]. In addition,
there was a higher risk of hospitalisation and deaths re-
lated to pertussis in HIV-exposed or HIV-infected in-
fants [34, 37, 38]. In considering their pertussis control
strategies, LMICs, which have the biggest burden of
HIV, need to take into account this increased risk asso-
ciated with HIV exposure and infection [8].
Our study is largely limited by paucity of data, espe-
cially longitudinal data for each included country as well
as vaccine coverage and number of vaccine doses re-
ceived in the specific population studied. The available
data was disproportionately provided by only a few
upper middle-income countries. A further limitation is
the case detection that may have been affected by the
variability of PCR assays used. In particular, this is noted
with respect to our inability to assess the sensitivity and
specificity of each assay. Regardless, our results will en-
courage generation of more epidemiological studies on
pertussis in LMICs, while in the meantime, assisting pol-
icy makers in disease control planning.
Conclusions
Immunisation remains suboptimal with vaccine coverage
with the three infant doses (DPT3) remaining low in
LMIC in general and in low-income countries, in par-
ticular [115]. Even where vaccine coverage with DPT3 is
acceptable, the doses are not often received in a timely
manner, undermining the protective effect of the vaccine
on young infants [116, 117]. Unlike in HIC countries in
which re-emergence of pertussis may be related to low
and delayed vaccine coverage secondary to vaccine hesi-
tancy, in LMIC, this usually reflects the lack of adminis-
trative capacity [118]. This study indicates an urgent
need to review and strengthen the existing pertussis con-
trol programmes in LMICs to target children, adoles-
cents and HIV-exposed and HIV-infected groups. In
addition, the study highlights the need to urgently con-
sider measures to reduce the high infant mortality rate,
with specific consideration for maternal vaccination.
There is now strong evidence to showing that immun-
isation of pregnant women, even when given as early as
the second trimester, is safe for both the mother and the
foetus and induces sufficient transplacental antibodies to
protect the young infant still too young to complete pri-
mary immunisation schedule for pertussis [119, 120]. In
their recommendation, the GPI in addition to priori-
tising surveillance and increasing overall vaccine
coverage made this an urgent area of action for
LMICs [6]. Encouragingly, we noted a substantial in-
crease in the number of studies published in the last
8 years of the period under review (2010–2018), pos-
sibly reflecting recent increase in interest and funding
for pertussis research in LMICs.
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